2017
THU-209 In hepatitis C virus-related advanced fibrosis and cirrhosis, early decline of liver stiffness following antiviral therapy with DAAs is related to decline in liver inflammation
Winters A, Luedtke S, Moreland A, Jangouk P, Weng G, Silveira M, Davitkov P, Duarte-Rojo A, Cheung R, Garcia-Tsao G, Falck-Ytter Y, Branch A, Bräu N. THU-209 In hepatitis C virus-related advanced fibrosis and cirrhosis, early decline of liver stiffness following antiviral therapy with DAAs is related to decline in liver inflammation. Journal Of Hepatology 2017, 66: s280. DOI: 10.1016/s0168-8278(17)30876-0.Peer-Reviewed Original Research
2016
Sa1645 Beta-Blocker (BB) Use in Hospitalized Cirrhotic Patients With Ascites Is Associated With a Lower MELD, Less Inflammation and an Improved Survival
Bhutta A, Garcia-Tsao G, Reddy K, Tandon P, Wong F, O'Leary J, Acharya C, Banerjee D, Abraldes J, Plener I, Jones T, Shaw J, Deng Y, Ciarleglio M, Bajaj J. Sa1645 Beta-Blocker (BB) Use in Hospitalized Cirrhotic Patients With Ascites Is Associated With a Lower MELD, Less Inflammation and an Improved Survival. Gastroenterology 2016, 150: s1084-s1085. DOI: 10.1016/s0016-5085(16)33659-9.Peer-Reviewed Original ResearchTHU-001 Beta-Blocker Use in Hospitalized Cirrhotic Patients with Ascites is Associated with a Lower Meld, less Inflammation and an Improved Survival
Bhutta A, Garcia-Tsao G, Reddy R, Tandon P, Wong F, O’Leary J, Acharya C, Banerjee D, Abraldes J, Plener I, Jones T, Shaw J, Deng Y, Ciarleglio M, Bajaj J. THU-001 Beta-Blocker Use in Hospitalized Cirrhotic Patients with Ascites is Associated with a Lower Meld, less Inflammation and an Improved Survival. Journal Of Hepatology 2016, 64: s245. DOI: 10.1016/s0168-8278(16)00253-1.Peer-Reviewed Original Research